Androgen deprivation therapy plus apalutamide as neoadjuvant therapy prior radical prostatectomy for patients with unresectable prostate cancer

Whether neoadjuvant therapy confers a survival benefit in advanced prostate cancer (PCa) remains uncertain. The primary endpoints of previous retrospective and phase II clinical studies that used neoadjuvant therapy, including androgen deprivation therapy combined with new-generation androgen recept...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Yongbao, Zhang, Ruochen, Zhong, Dewen, Chen, Zhensheng, Chen, Gen, Yang, Minggen, Lin, Le, Li, Tao, Ye, Liefu, Chen, Lili, Zhu, Qingguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620516/
https://www.ncbi.nlm.nih.gov/pubmed/37927597
http://dx.doi.org/10.3389/fphar.2023.1284899

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620516/
https://www.ncbi.nlm.nih.gov/pubmed/37927597
http://dx.doi.org/10.3389/fphar.2023.1284899

Ejemplares similares